Seleno Therapeutics was founded in 2015 as a spin-off company of the Australian Research Council Centre of Excellence for Free Radical Chemistry and Biotechnology. 

​

The Centre was generously funded by the Australian Research Council (2005–2013) and was a collaboration of a number of universities and research organisations. Researchers at the Heart Research Institute (Sydney) and the University of Melbourne, through a collaborative Centre-funded research project, invented the technology that is being further developed by the Company.

​

Seleno Therapeutics is fully independent of both the University of Melbourne and the Heart Research Institute and fully owns the Intellectual Property on which it is based.

​

The Company's current activities are funded through investments made by the Team, a consortium of private investors, and a research grant. We are currently involved in projects in Australia, Denmark, Italy, Brazil, and Austria.

​

Seleno Therapeutics is governed by a Board of Directors that include Ina Sambor (CEO), Carl Schiesser, and Mike Davies.